Thus, our data provide the foundation to investigate the presence and loss of pRb-Ser780 as a biomarker of acquired resistance to BRAF/MEK inhibition and a biomarker of response to BRAF/MEK/CDK4/6 therapy in BRAFV600E-mutant melanomas, respectively. This evidence concerns the gene RB1 and melanoma.